Pumafentrine
Alternative Names: BY 343Latest Information Update: 23 Jan 2003
At a glance
- Originator ALTANA Pharma
- Class Anti-inflammatories; Antipsoriatics; Naphthyridines; Small molecules
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Psoriasis
Most Recent Events
- 23 Jan 2003 Discontinued - Phase-I for Asthma in European Union (PO)
- 23 Jan 2003 Discontinued - Phase-I for Chronic obstructive pulmonary disease in USA (PO)
- 23 Jan 2003 Discontinued - Phase-II for Asthma in USA (PO)